首頁 > 市場調查報告書 > 製藥

醫藥品原料藥

市場調查報告書

商品編碼

1392257

全球微生物 API 市場研究報告 - 2023 年至 2030 年產業分析、規模、佔有率、成長、趨勢和預測

Global Microbial API Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年11月01日 | 出版商:

Value Market Research | 英文 335 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

預計到 2030 年，全球微生物 API 市場需求將從 2022 年的 602.1 億美元達到近 1,050.9 億美元的市場規模，2023-2030 年研究期間CAGR為 7.21%。

微生物API是指源自微生物的活性藥物成分，例如細菌、真菌或其他微生物。這些原料藥是藥物中的核心治療成分，對身體有藥理作用。

市場動態：

微生物 API 市場的成長是由多個相互關聯的因素所推動的。由於感染和抗生素抗藥性的增加，對抗生素的需求增加，推動了對微生物源 API 的需求。技術進步，特別是生物技術和基因工程的進步，徹底改變了微生物發酵，使其生產複雜 API 的效率更高且更具成本效益。製藥業的擴張和對創新藥物的追求極大地增加了對多種微生物 API 的需求，特別是隨著對生物製藥的關注不斷加強。支持藥物安全性和有效性的政府法規，以及促進新藥開發的舉措，對這個市場產生了正面影響。製藥公司和研究機構之間的合作，加上對研發的大量投資，加速了微生物 API 的發現和生產。在醫療保健支出和意識增加的推動下，新興經濟體市場的擴張進一步刺激了對負擔得起的藥物的需求。此外，微生物原料藥生產方法的環境永續性使其相對於傳統化學合成更受青睞，為微生物製藥製造帶來了光明的未來。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球微生物原料藥市場的各個細分市場進行了包容性評估。微生物原料藥產業的成長和趨勢為本研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲微生物 API 市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。微生物原料藥市場的主要參與者包括默克公司、天方藥業有限公司、帝斯曼、石藥Group Limited、可隆生命科學、山東魯抗製藥有限公司、梯瓦製藥工業有限公司。，龍沙。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

簡介 - 市場動態
市場促進因素
市場限制
機會
產業動態
波特五力分析
市場吸引力分析
- 主辦單位市場吸引力分析
- 按類型分類的市場吸引力分析
- 按網站分類的市場吸引力分析
- 按最終用途分類的市場吸引力分析
- 分子市場吸引力分析
- 市場吸引力分析：按地區

第 4 章：價值鏈分析

價值鏈分析
原料分析
- 原料清單
- 原料廠商清單
- 主要原物料價格走勢
潛在買家名單
行銷管道
- 直效行銷
- 間接行銷
- 行銷通路發展趨勢

第 5 章：全球微生物 API 市場分析：依主機分類

主持人概述
歷史和預測數據
主持人分析
哺乳動物
細菌
真菌

第 6 章：全球微生物 API 市場分析：按類型

按類型概述
歷史和預測數據
按類型分析
抗體
胜肽
蛋白質
小分子
疫苗

第 7 章：全球微生物 API 市場分析：按地點

按站點概述
歷史和預測數據
按站點分析
內部
外包

第 8 章：全球微生物 API 市場分析：依最終用途分類

按最終用途分類的概述
歷史和預測數據
按最終用途分析
製藥公司
生物製藥公司
其他

第 9 章：全球微生物 API 市場分析：按分子

分子概述
歷史和預測數據
分子分析
創新的
通用的

第 10 章：全球微生物 API 市場分析：依地理位置

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 11 章：微生物 API 公司的競爭格局

微生物原料藥市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 12 章：公司簡介

公司股份分析
市場集中度
Merck & Co. Inc.

公司簡介
公司收入
產品
最近的發展

Topfond Pharmaceutical Co. Ltd.

公司簡介
公司收入
產品
最近的發展

公司簡介
公司收入
產品
最近的發展

CSPC Pharmaceutical Group Limited

公司簡介
公司收入
產品
最近的發展

KOLON LIFE SCIENCE

公司簡介
公司收入
產品
最近的發展

Shandong Lukang Pharmaceutical Co. Ltd.

公司簡介
公司收入
產品
最近的發展

Teva Pharmaceutical Industries Ltd.

公司簡介
公司收入
產品
最近的發展

Lonza

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112112866

The global demand for Microbial API Market is presumed to reach the market size of nearly USD 105.09 BN by 2030 from USD 60.21 BN in 2022 with a CAGR of 7.21% under the study period 2023 - 2030.

Microbial API refers to Active Pharmaceutical Ingredients derived from microorganisms, such as bacteria, fungi, or other microorganisms. These APIs are the core therapeutic components in medications that exert a pharmacological effect on the body.

MARKET DYNAMICS:

The microbial API market's growth is driven by multiple interconnected factors. Heightened demand for antibiotics due to increasing infections and antibiotic resistance propels the need for microbial-derived APIs. Technological advancements, particularly in biotechnology and genetic engineering, have revolutionized microbial fermentation, making it more efficient and cost-effective for producing complex APIs. The pharmaceutical industry's expansion and pursuit of innovative drugs contribute significantly to the demand for diverse microbial APIs, especially as the focus on biopharmaceuticals intensifies. Government regulations supporting drug safety and efficacy, alongside initiatives promoting new drug development, positively influence this market. Collaborations between pharmaceutical firms and research institutions, coupled with substantial investments in R&D, accelerate microbial API discovery and production. The market's expansion in emerging economies, driven by increased healthcare spending and awareness, further fuels the demand for affordable medications. Additionally, the environmental sustainability of microbial API production methods has led to their preference over traditional chemical synthesis, fostering a promising future for microorganism-based pharmaceutical manufacturing.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of microbial api. The growth and trends of microbial api industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the microbial api market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Host

Mammalian
Bacterial
Fungal

By Type

Antibody
Peptide
Protein
Small Molecule
Vaccine

By Site

In-House
Outsourced

By End-Use

Pharmaceutical Companies
Biopharmaceutical Companies
Others

By Molecule

Innovative
Generic

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Microbial API market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Microbial API market include Merck & Co., Inc., Topfond Pharmaceutical Co., Ltd., DSM, CSPC Pharmaceutical Group Limited, KOLON LIFE SCIENCE, Shandong Lukang Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Lonza. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . MICROBIAL API - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Host
- 3.7.2 Market Attractiveness Analysis By Type
- 3.7.3 Market Attractiveness Analysis By Site
- 3.7.4 Market Attractiveness Analysis By End-use
- 3.7.5 Market Attractiveness Analysis By Molecule
- 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL MICROBIAL API MARKET ANALYSIS BY HOST

5.1 Overview by Host
5.2 Historical and Forecast Data
5.3 Analysis by Host
5.4 Mammalian Historic and Forecast Sales by Regions
5.5 Bacterial Historic and Forecast Sales by Regions
5.6 Fungal Historic and Forecast Sales by Regions

6 . GLOBAL MICROBIAL API MARKET ANALYSIS BY TYPE

6.1 Overview by Type
6.2 Historical and Forecast Data
6.3 Analysis by Type
6.4 Antibody Historic and Forecast Sales by Regions
6.5 Peptide Historic and Forecast Sales by Regions
6.6 Protein Historic and Forecast Sales by Regions
6.7 Small Molecule Historic and Forecast Sales by Regions
6.8 Vaccine Historic and Forecast Sales by Regions

7 . GLOBAL MICROBIAL API MARKET ANALYSIS BY SITE

7.1 Overview by Site
7.2 Historical and Forecast Data
7.3 Analysis by Site
7.4 In-house Historic and Forecast Sales by Regions
7.5 Outsourced Historic and Forecast Sales by Regions

8 . GLOBAL MICROBIAL API MARKET ANALYSIS BY END-USE

8.1 Overview by End-use
8.2 Historical and Forecast Data
8.3 Analysis by End-use
8.4 Pharmaceutical Companies Historic and Forecast Sales by Regions
8.5 Biopharmaceutical Companies Historic and Forecast Sales by Regions
8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL MICROBIAL API MARKET ANALYSIS BY MOLECULE

9.1 Overview by Molecule
9.2 Historical and Forecast Data
9.3 Analysis by Molecule
9.4 Innovative Historic and Forecast Sales by Regions
9.5 Generic Historic and Forecast Sales by Regions

10 . GLOBAL MICROBIAL API MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1. Overview, Historic and Forecast Data Sales Analysis
- 10.3.2. North America By Segment Sales Analysis
- 10.3.3. North America By Country Sales Analysis
- 10.3.4. United State Sales Analysis
- 10.3.5. Canada Sales Analysis
- 10.3.6. Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1. Overview, Historic and Forecast Data Sales Analysis
- 10.4.2. Europe by Segment Sales Analysis
- 10.4.3. Europe by Country Sales Analysis
- 10.4.4. United Kingdom Sales Analysis
- 10.4.5. France Sales Analysis
- 10.4.6. Germany Sales Analysis
- 10.4.7. Italy Sales Analysis
- 10.4.8. Russia Sales Analysis
- 10.4.9. Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1. Overview, Historic and Forecast Data Sales Analysis
- 10.5.2. Asia Pacific by Segment Sales Analysis
- 10.5.3. Asia Pacific by Country Sales Analysis
- 10.5.4. China Sales Analysis
- 10.5.5. India Sales Analysis
- 10.5.6. Japan Sales Analysis
- 10.5.7. South Korea Sales Analysis
- 10.5.8. Australia Sales Analysis
- 10.5.9. South East Asia Sales Analysis
- 10.5.10. Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1. Overview, Historic and Forecast Data Sales Analysis
- 10.6.2. Latin America by Segment Sales Analysis
- 10.6.3. Latin America by Country Sales Analysis
- 10.6.4. Brazil Sales Analysis
- 10.6.5. Argentina Sales Analysis
- 10.6.6. Peru Sales Analysis
- 10.6.7. Chile Sales Analysis
- 10.6.8. Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1. Overview, Historic and Forecast Data Sales Analysis
- 10.7.2. Middle East & Africa by Segment Sales Analysis
- 10.7.3. Middle East & Africa by Country Sales Analysis
- 10.7.4. Saudi Arabia Sales Analysis
- 10.7.5. UAE Sales Analysis
- 10.7.6. Israel Sales Analysis
- 10.7.7. South Africa Sales Analysis
- 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE MICROBIAL API COMPANIES

11.1. Microbial Api Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12 . COMPANY PROFILES OF MICROBIAL API INDUSTRY

12.1. Company Share Analysis
12.2. Market Concentration Rate
12.3. Merck & Co. Inc.
- 12.3.1. Company Overview
- 12.3.2. Company Revenue
- 12.3.3. Products
- 12.3.4. Recent Developments
12.4. Topfond Pharmaceutical Co. Ltd.
- 12.4.1. Company Overview
- 12.4.2. Company Revenue
- 12.4.3. Products
- 12.4.4. Recent Developments
12.5. DSM
- 12.5.1. Company Overview
- 12.5.2. Company Revenue
- 12.5.3. Products
- 12.5.4. Recent Developments
12.6. CSPC Pharmaceutical Group Limited
- 12.6.1. Company Overview
- 12.6.2. Company Revenue
- 12.6.3. Products
- 12.6.4. Recent Developments
12.7. KOLON LIFE SCIENCE
- 12.7.1. Company Overview
- 12.7.2. Company Revenue
- 12.7.3. Products
- 12.7.4. Recent Developments
12.8. Shandong Lukang Pharmaceutical Co. Ltd.
- 12.8.1. Company Overview
- 12.8.2. Company Revenue
- 12.8.3. Products
- 12.8.4. Recent Developments
12.9. Teva Pharmaceutical Industries Ltd.
- 12.9.1. Company Overview
- 12.9.2. Company Revenue
- 12.9.3. Products
- 12.9.4. Recent Developments
12.10. Lonza
- 12.10.1. Company Overview
- 12.10.2. Company Revenue
- 12.10.3. Products
- 12.10.4. Recent Developments